(Q35582517)

9 August 2017

1 reference

title

Tumour necrosis factor in sarcoidosis and its potential for targeted therapy (English)

1 reference

9 August 2017

Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy (English)

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

1 April 2024

0 references

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

1 April 2024

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

1 April 2024

1

Robert P Baughman

1 reference

9 August 2017

Michael Iannuzzi

2

1 reference

9 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14614765

1 April 2024

publication date

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

17

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

425-431

1 reference

https://scigraph.springernature.com/pub.10.2165/00063030-200317060-00005

9 August 2017

exact match

0 references

cites work

An endotoxin-induced serum factor that causes necrosis of tumors

1

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Identity of tumour necrosis factor and the macrophage-secreted factor cachectin

1 April 2024

2

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

The tumor necrosis factor ligand and receptor families.

1 April 2024

3

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Lymphocyte Cytotoxicity in vitro: Activation and Release of a Cytotoxic Factor

1 April 2024

4

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin

1 April 2024

5

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex

1 April 2024

6

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

1 April 2024

7

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Hematologic interactions of endotoxin, tumor necrosis factor alpha (TNF alpha), interleukin 1, and adrenal hormones and the hematologic effects of TNF alpha in Corynebacterium parvum-primed rats

1 April 2024

9

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

1 April 2024

10

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

1 April 2024

11

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 April 2024

12

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn disease

1 April 2024

13

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

The Journal of Rheumatology

1 April 2024

14

27

841

Kavanaugh

2000

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 April 2024

15

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

NIH conference. Pulmonary sarcoidosis: a disease characterized and perpetuated by activated lung T-lymphocytes

1 April 2024

16

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis

1 April 2024

17

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation

1 April 2024

18

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis

1 April 2024

19

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

The American Review of Respiratory Disease

1 April 2024

20

129

563

Ceuppens

1984

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Th1/Th2 cell distribution in pulmonary sarcoidosis

1 April 2024

21

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis

1 April 2024

22

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs

1 April 2024

23

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 April 2024

26

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 April 2024

27

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis

1 April 2024

30

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and interleukin-6 but not interleukin-1 beta

1 April 2024

31

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers

1 April 2024

32

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation

1 April 2024

33

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

The gene polymorphism of tumor necrosis factor-beta, but not that of tumor necrosis factor-alpha, is associated with the prognosis of sarcoidosis

1 April 2024

34

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis

1 April 2024

35

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Anti-idiotypes and autoimmune disease.

1 April 2024

36

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

1 April 2024

37

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor

1 April 2024

38

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

TNF-R1 signaling: a beautiful pathway

1 April 2024

39

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids

1 April 2024

40

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function

1 April 2024

41

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance.

1 April 2024

42

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

1 April 2024

44

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline

1 April 2024

45

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis

1 April 2024

49

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial

1 April 2024

50

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy

1 April 2024

51

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis

1 April 2024

52

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Outcome of the treatment for sarcoidosis

1 April 2024

54

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

A clinical approach to the use of methotrexate for sarcoidosis

1 April 2024

56

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Prolonged use of methotrexate for sarcoidosis

1 April 2024

57

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Low-dose methotrexate therapy for childhood sarcoidosis

1 April 2024

58

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Diagnosis and management of neurological sarcoidosis

1 April 2024

59

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen

1 April 2024

60

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages.

1 April 2024

63

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages

1 April 2024

64

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Pentoxifylline in treatment of sarcoidosis

1 April 2024

65

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.

1 April 2024

66

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Thalidomide for chronic sarcoidosis

1 April 2024

67

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report

1 April 2024

68

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Cutaneous sarcoidosis successfully treated with low doses of thalidomide

1 April 2024

69

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages.

1 April 2024

71

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Antitumor activity of thalidomide in refractory multiple myeloma

1 April 2024

74

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 April 2024

75

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Treatment of fistulas in Crohn's disease with infliximab

1 April 2024

76

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 April 2024

77

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 April 2024

78

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

1 April 2024

79

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 April 2024

80

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy

1 April 2024

82

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis

1 April 2024

84

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease

1 April 2024

85

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

1 April 2024

86

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases

1 April 2024

87

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

Anti-cytokine therapy for rheumatoid arthritis

1 April 2024

88

1 reference

https://api.crossref.org/works/10.2165/00063030-200317060-00005

1 April 2024

Identifiers

1 reference

Dimensions Publication ID

9 August 2017

1012275233

0 references

1 reference